ResMed Form 4: Director Ronald Taylor receives 1,073 RSUs

Rhea-AI Filing Summary

ResMed Inc. (RMD) reported a change in director ownership through a Form 4 filing. Director Ronald Taylor received an award of 1,073 shares of ResMed common stock on 11/20/2025 at a stated price of $0, reflecting a grant rather than an open-market purchase. Following this transaction, he beneficially owns 24,771 shares directly.

The shares awarded are in the form of Restricted Stock Units (RSUs). These RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, aligning the director’s compensation with the company’s long-term performance and shareholder interests.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TAYLOR RONALD R

(Last) (First) (Middle)

138 WEST CANOE POINT ROAD

(Street)

COOLIN ID 83821

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	11/20/2025		A(1)		1,073	A	$0	24,771	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares awarded represent Restricted Stock Units. The RSUs vest in full on the earlier of 11/11/2026, or the annual meeting of stockholders in the year following the grant date.

	Ronald Taylor, Director	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ResMed (RMD) report for Ronald Taylor?

ResMed reported that Director Ronald Taylor was awarded 1,073 shares of ResMed common stock on 11/20/2025, recorded at a price of $0, as part of his equity compensation.

How many ResMed (RMD) shares does Ronald Taylor own after this Form 4 transaction?

After the reported transaction, Ronald Taylor beneficially owns 24,771 shares of ResMed common stock in direct ownership.

What type of equity award did Ronald Taylor receive from ResMed (RMD)?

The filing states that the 1,073 shares represent Restricted Stock Units (RSUs), which are share-based awards that vest over time.

When do Ronald Taylor’s RSUs in ResMed (RMD) vest?

The RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date.

Is Ronald Taylor a director or officer of ResMed (RMD)?

The Form 4 identifies Ronald Taylor as a Director of ResMed Inc., with the director box checked and no officer title provided.

Was this ResMed (RMD) transaction part of a Rule 10b5-1 plan?

The form includes a checkbox for indicating Rule 10b5-1 plans, but the provided content does not show that this transaction was designated as made under such a plan.